Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies-Reference-Cited by-同舟云学术

Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies

Published:2012-01-01 Issue:1 Volume:59 Page:39-46
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Rimsky Laurence,Vingerhoets Johan,Van Eygen Veerle,Eron Joseph,Clotet Bonaventura,Hoogstoel Annemie,Boven Katia,Picchio Gaston

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference18 articles.

1. For the ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.;Molina;Lancet,2011

2. For the THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.;Cohen;Lancet,2011

3. TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.;Pozniak;AIDS,2010

4. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C - C181I) RT HIV-1 mutants.;Balzarini;Proc Natl Acad Sci U S A,1994

5. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.;Tambuyzer;J Acquir Immune Defic Syndr,2011

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015–21;Journal of Antimicrobial Chemotherapy;2024-07-19

2. Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

3. Characterization of Human Immunodeficiency Virus-1 Transmission Clusters and Transmitted Drug-Resistant Mutations in Croatia from 2019 to 2022;Viruses;2023-12-11

4. Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2-d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants;Acta Pharmaceutica Sinica B;2023-11

5. Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis;Virology Journal;2023-10-25